Stryker has completed the acquisition of OrthoSpace, developer and marketer of orthopedic biodegradable balloon systems in an all cash transaction for an upfront payment of $110m and future milestone payments of up to an additional $110m. OrthoSpace’s product portfolio provides a highly differentiated technology for the treatment of massive irreparable rotator cuff tears. The InSpace product is a biodegradable sub-acromial spacer, which is designed to realign the natural biomechanics of the shoulder. The technology has a long clinical history with over 20k patients treated across 30 countries. In the US, InSpace is currently under clinical study and not approved for use. “The acquisition of OrthoSpace is highly complementary to our existing portfolio and aligns with Stryker’s focus on investing in sports medicine. We are excited about the momentum OrthoSpace has in key global markets and the additional surgical option this technology provides our customers to address a complex pathology,” Andy Pierce, Stryker’s Group President, MedSurg.